Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an overall 5 year-survival rate of just 5%. A better understanding of the carcinogenesis processes and the mechanisms of progression of PDAC is mandatory.
Fifty-two PDAC patients treated with surgery and adjuvant therapy, with available primary tumor, normal tissue, preneoplastic lesions (PanIN), and/or lymph node metastases, were selected for the study. Proteins were extracted from small punches and analyzed by LC-MS/MS using data-independent acquisition. Proteomics data was analyzed using probabilistic graphical models, allowing functional characterization. Comparisons between groups were done using linear mixed models. Three proteomics tumor subtypes were defined. T1 (32% of patients) was related to adhesion, T2 (34%) had metabolic features, and T3 (34%) presented high splicing and nucleoplasm activity. These proteomics subtypes were validated in the PDAC TCGA cohort. Relevant biological processes related to carcinogenesis and tumor progression were studied in each subtype. Carcinogenesis in T1 subtype seems to be related to an increase of adhesion and complement activation nodes activity, whereas tumor progression seems to be related to nucleoplasm and translation nodes. Regarding T2 subtype, it seems that metabolism and, especially, mitochondria act as the motor of cancer development. T3 analyses point out that nucleoplasm, mitochondria and metabolism, and extracellular matrix nodes could be involved in T3 tumors carcinogenesis. Identified processes were different among proteomics subtypes, suggesting that the molecular motor of the disease is different in each subtype. These differences can have implications in the development of future tailored therapeutic approaches for each PDAC proteomics subtype.
Competing Interest Statement
AG-P and JAFV are shareholders of Biomedica Molecular Medicine SL. EL-C and AZ-M are employees of Biomedica Molecular Medicine SL.
Funding Statement
MI-LH and AZ-M are supported by Consejeria de Educacion e Investigacion of Comunidad de Madrid (IND2018/BMD-9262). EL-C is supported by the Spanish Economy and Competitiveness Ministry (PTQ2018-009760).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethical Committee from Hospital Universitario La Paz (IRB number: 1349).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data have been deposited to the ProteomeXchange Consortium via the PRIDE (http://www.ebi.ac.uk/pride) partner repository with the data set identifier PXD032076 and it will be available since the publication of the study.
